Strategies to prevent persistent or relapsed mixed cryoglobulinemia - Sorbonne Université
Journal Articles Expert Opinion on Orphan Drugs Year : 2020

Strategies to prevent persistent or relapsed mixed cryoglobulinemia

Abstract

Mixed cryoglobulinemia (MC) are immune complexes that can deposit in small and medium size arteries and cause systemic vasculitis called cryoglobulinemic vasculitis (CryoVas). CryoVas most common clinical manifestations include purpura, arthralgia and/or arthritis, skin ulcers, peripheral neuropathy, nephritis, and may progress to more life-threatening illness. Hepatitis C virus (HCV) infection is the more frequent condition to be assessed in patients with MC, followed by connective tissue diseases and B-cell non-Hodgkin’s lymphoma. In HCV-related cases, the mainstay of CryoVas treatment is interferon free antiviral therapy. However, a significant proportion of patients who show HCV eradication will develop persistent CryoVas needing treatment intensification.
Fichier principal
Vignette du fichier
Boleto et al. - 2020 - Strategies to prevent persistent or relapsed mixed.pdf (251.51 Ko) Télécharger le fichier
Origin Files produced by the author(s)
Loading...

Dates and versions

hal-02998024 , version 1 (10-11-2020)

Identifiers

Cite

Gonçalo Boleto, David Saadoun, Patrice Cacoub. Strategies to prevent persistent or relapsed mixed cryoglobulinemia. Expert Opinion on Orphan Drugs, 2020, 8 (5), pp.137-143. ⟨10.1080/21678707.2020.1767586⟩. ⟨hal-02998024⟩
43 View
175 Download

Altmetric

Share

More